chrisvoncsefalvay/vaers-outcomes huggingface dataset:
hurt himself; This is a spontaneous report from a contactable consumer (patient's wife) via a Pfizer-sponsored program. A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. It was reported that the patient hurt himself on an unspecified date and was treated with a tetanus shot and antibiotics (unspecified). The patient was reportedly scheduled for his second dose on 16Apr2021; the patient's wife was inquiring if this would affect the vaccine. Outcome of event was unknown.  Information about lot/batch has been requested.
She reported that after getting her flu shot and PNEUMOVAX 23 2 weeks ago she was out of commission for the weekend; her arm swelled up (had swelling from elbow to wrist) and she broke out in hives. Stated for the first day she felt like a zombie - also had some shortness of breath, but not a problem now. Has to take BENADRYL to control; her dermatologist has her take up to 100mg dose. The arm she received the flu shot continues to itch. Has used topical steroids without relief and also has a little rash on the eyelids.
24hr p/vax c/o bad h/a;temp remained 102 given APAP or motrin q 4hr;c/o stomach pain, legs & back pain, neck pain;
Patient's wife called with concerns that patient was complaining of chills and his entire body hurting.
Stomach cramps,  nausea, diarrhea every day, off and on since shot.
This service member received Anthrax #1 on 10 Dec 02, #2 on 8 Jan 03, #3 on 21 Jan, and the smallpox vaccine on 6 Feb 03. He was in his usual state of good health when he deployed in Apr 2003. While deployed his neurologic symptoms started so gradually that he is unable to state when they first appeared. It was other men in his unit who pointed out to him that there was "something wrong". They noticed a change in his speech, that he stumbled, walked with a limp and had lost a lot of weight (from 200 lbs to 140 lbs). He does recall that his limp started about Oct 03. He returned home in Apr 04 and by his 22nd birthday on 7 May he was confined to a wheelchair unable to walk. Eight months later he was diagnosed with SCA spinocerebella ataxia type 8 by a doctor. Symptoms: Gait abnormality, Hyper-reflexia, Weakness, Weight loss, unexpected.   10/14/08 Reviewed medical records of 9/12/2008. FINAL DX: spinocerebellar ataxia Records reveal patient experienced usual state of good health when vaccinated w/anthrax & smallpox vaccines 2003.  While deployed, developed gradual onset of neurologic symptoms: speech changes, stumbling gait, limping, weight loss of 60# until became unable to walk by 5/2004.  10/24/08 Reviewed neuro clinic medical records of 8/12-8/16/2004. FINAL DX: none provided Records reveal patient experienced ataxia since approx 1/2004 w/difficulty walking, ascending/descending stairs, excessive fatigability, 80# weight loss, speech difficulty, balance difficulty, frequent falls.  Had been hospitalized x 3 wks after deployment, became w/c bound by 5/2004 & had numbness/tingling in all extremities w/profound loss of position sense in LEs.  Exam revealed spastic LEs w/clonus, marked incoordination, truncal titubation, difficulty standing.
This case was reported by a consumer via  interactive digital media and described the occurrence of sickness in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced sickness. On an unknown date, the outcome of the sickness was unknown.  Additional details were provided as follows: The reporter was the concerned patient. The age at vaccination was not reported. The reporter stated that he/she got one of the shingles vaccines and it made him/her sicker than a dog. The reporter stated he/she was not going back for another. The reporter stated that he/she did not believe anything they tell them anymore. The follow-up would not be possible as no contact details were available.
Injection site is extremely swollen, red and raised.  Swelling and knot underneath the skin is extremely large and painful.  Itching.  Symptoms didn't appear until 8 days after shot.
4-5 hrs after receiving Influenza vaccine, pt experienced respiratory distress & fever of 105. Hospitalized for 3 days.
I started menstrual bleeding the night I got first shot; This spontaneous case was reported by a consumer and describes the occurrence of INTERMENSTRUAL BLEEDING (I started menstrual bleeding the night I got first shot) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INTERMENSTRUAL BLEEDING (I started menstrual bleeding the night I got first shot). At the time of the report, INTERMENSTRUAL BLEEDING (I started menstrual bleeding the night I got first shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. Treatment information was not provided.
pt recvd vax 22MAy95;24hrs later pt devel transient rash of 1-2 days duration;3JUL95 pt devel a subclinical case varicella;had pruritic vesicular rash which lasted about 4 days;5JUL95 dx w/chicken pox;MD felt was secondary transmission
Diagnosed with shingles; the rash is on my torso and in the back; I couldn't sleep at night; The pain was excruciating; Discomfort pains in center of chest; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of CHEST PAIN (Discomfort pains in center of chest), CHEST PAIN (The pain was excruciating) and HERPES ZOSTER (Diagnosed with shingles) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (medical history was not reported.). Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID) and HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM (HYZAAR) for an unknown indication.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, the patient experienced CHEST PAIN (Discomfort pains in center of chest) (seriousness criterion medically significant). On 27-Mar-2021, the patient experienced CHEST PAIN (The pain was excruciating) (seriousness criterion medically significant) and INSOMNIA (I couldn't sleep at night). On 28-Mar-2021, the patient experienced HERPES ZOSTER (Diagnosed with shingles) (seriousness criterion medically significant) and RASH (the rash is on my torso and in the back). At the time of the report, CHEST PAIN (Discomfort pains in center of chest), CHEST PAIN (The pain was excruciating), HERPES ZOSTER (Diagnosed with shingles), INSOMNIA (I couldn't sleep at night) and RASH (the rash is on my torso and in the back) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment for the event included  Famciclovir for 7 days initially and Acyclovir ointment for the Shingles rash and Celebrex for the pain.  This case concerns a 70-year-old female with a serious unexpected event of chest pain and herpes zoster, and nonserious unexpected insomnia and rash. Event onset 2 days after first dose mRNA-1273. Event outcomes unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: This case concerns a 70-year-old female with a serious unexpected event of chest pain and herpes zoster, and nonserious unexpected insomnia and rash. Event onset 2 days after first dose mRNA-1273. Event outcomes unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
patient stated that 1-2 days after immunization their arm become inflamed and almost purple. It was painful and has slowly returned to normal. Some nerve sensations are felt.
PAIN ON LEFT LEG IN THE BACK  OF CALF INTO THE KNEE AND INTO THE LOWER THIGH; CHILLS; This spontaneous report received from a patient via a company representative concerned a 64 year old female. The patient's weight was 145 pounds, and height was 64 inches. The patient's concurrent conditions included: alcohol user occasionally, non smoker, and thyroid, and other pre-existing medical conditions included: The patient had no known allergy and no drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808980 expiry: 20-JUL-2021) dose was not reported, administered on 01-APR-2021 for prophylactic vaccination. Concomitant medications included levothyroxine for thyroid disorder.  On 01-APR-2021, the patient experienced chills. On 07-APR-2021, the patient experienced pain on left leg in the back of calf into the knee and into the lower thigh. On 13-APR-2021, Laboratory data included: Sonogram (NR: not provided) negative. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills on 02-APR-2021, and was recovering from pain on left leg in the back of calf into the knee and into the lower thigh. This report was non-serious.
This non-serious spontaneous case, initially received from other non-health professional on 13-Nov-2018, concerns an 80-year-old, elderly patient of an unspecified gender. It was reported that, the FLUAD (TIV) vaccine underwent temperature excursion for the first time. The vaccine was out for around 48 hours and it reached 11.6 degree Celsius. On 19-Oct-2018, the patient was administered FLUAD (TIV) [batch number: 250802, dose, route of administration, anatomical location and expiry date: not reported] which underwent temperature excursion. At the time of this report, no adverse event was reported. This case 201805515 was crossed linked to original cases 201804863 due to same reporter.
Treatment of COVID-19; Treatment of COVID-19; Vaccine brand=Pfizer/BioNTech, vaccine dose number=1, 2, 3/Vaccine brand other=Moderna, Vaccine dose number=4, 5; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old male patient received BNT162b2 (BNT162B2), on 20Jan2021 as dose 1, single (Lot number: EL3247), in left arm, on 10Feb2021 as dose 2, single (Lot number: EM9810), in left arm and on 15Oct2021 as dose 3 (booster), single (Lot number: FF2589) at the age of 68 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 25Mar2022 as dose 4 (booster), single (Lot number: 042121A), in left arm and on 25Sep2022 as dose 5 (booster), single (Lot number: AS7164B), in right arm for covid-19 immunisation. The patient's relevant medical history included: "seizure disorder" (unspecified if ongoing); "cancer (base of tongue)" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 25Mar2022, outcome "unknown", described as "Vaccine brand=Pfizer/BioNTech, vaccine dose number=1, 2, 3/Vaccine brand other=Moderna, Vaccine dose number=4, 5"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19.
Information has been received from a registered nurse concerning a patient who was vaccinated with PNEUMOVAX 23 vaccine and experienced adverse events.  The patient had unspecified adverse event and went to the hospital.  Unspecified if patient had been admitted.  Name of the hospital was unspecified.  The patient had sought unspecified medical attention.  At the time of the report, the patient's status was unknown.  Follow up information has been received from a registered nurse concerning a 36 year old male who was vaccinated with a dose of PNEUMOVAX 23 vaccine (lot # 663152/0024Y) IM in the left arm on an unspecified date.  Concomitant therapy included tuberculin purified protein derivative (lot # C3060aa) SC in the right arm on 25-AUG-2009 at 11:24 AM.  The patient had a history of therapy with aspirin for the treatment of throat swelling, ZESTRIL for the treatment of cough, SILENOR for the treatment of rash, and bee sting which increased blood pressure.  On 25-AUG-2009 at 9:15 PM the patient complained of fever at 103F, disorientation, myalgia, and feeling achy.  Lab data included chest x-ray, normal; white blood cells count, not elevated; urinalysis, normal; no Gastrointestinal symptoms.  The patient was discharged to home with recommendation for PCP follow up.  On 26-AUG-2009, the PCP follow up listed that the patient reported that the condition improved when the fever decreased.  The patient required ER visit.  The patient recovered on 26-AUG-2009.  This is one of several reports received from the same source.  No further information is available.
Vaccine administered on 9/8. Developed chest pain and shortness of breath on 9/9 and self resolved. Developed chest pain and burning on 9/10. Symptom duration unknown.  Patient without fever, cough, congestion, or other infectious symptoms prior to vaccination and after vaccination.  On 9/12 symptoms returned and patient's father took him to the emergency department.
SEVERE CHILLS, FEVER OF 101, ACHING IN KNEES AND ANKLES, HEADACHE, LACK OF APPETITE; LASTED 2 DAYS
This spontaneous report as received from a Licensed Practical Nurse refers to unspecified patients of unknown age and gender. The nurse reported that on an unknown date these unspecified patients received improperly stored (Oka/Merck) VARIVAX (lot #, dose, route, indication not reported) exposed to -9C for an undetermined time frame. Concomitant therapy was not reported. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Muscle pain; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Muscle pain) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced MYALGIA (Muscle pain). On 21-Jan-2021, MYALGIA (Muscle pain) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No Concomitant medication was reported. No treatment information was provided.   This case was linked to MOD-2021-023445, MOD-2022-662026 (Patient Link).   Reporter did not allow further contact
Heart rates increased to 110 (baseline is only 50s or 60s); fainting, lethargy (altered mental status); weakness; could not walk (baseline can handle daily living independently). Called 911 on 09/27/18.
The patient described a local injection site red reaction after the vaccine, and then a fine red itchy bumpy rash that started on her legs and spread to most of her body over the next week or so.  She was seen by Dr. on 3/01 and evaluated.  He felt the rash was most likely an allergic reaction to the vaccine.  He concurred with the patient's assesment of the injection site reaction and rash.  The patient also reported low-grade headache but no fever or chills or other symptoms.  He did not feel the rash was a varicella-type rash.  He prescribed OTC diphenhydramine 25-50 mg every 4 hours as needed and cool baths.  As of 3/12/12, the patient reports improvement but still a rash on arms.
After being infected by my son in law who is also vaccinated with the Pfizer vaccine; After being infected by my son in law who is also vaccinated with the Pfizer vaccine; This is a spontaneous report received from a contactable consumer via a Pfizer sponsored program. A male patient of an unspecified age received bnt162b2 (PFIZER-COVID19 VACCINE,Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as Dose number unknown,single for covid-19 immunization .The patient medical history and concomitant medications were not reported.The patient got infected with covid-19 after being infected by his son in law who was also vaccinated with the pfizer vaccine on an unspecified date.The patient underwent lab tests and procedures which included sars-cov-2 test: positive on Wednesday July14.The patient reported that he was fully vaccinated in February.The outcome of the event was unknown.  Information on lot /batch number has been requested.
pt recvd vax;devel t 104.8 R;became lethargic on 13dec94 in eve;mom called 14dec;was instructed to call MD;to MD 13dec ,given pediaprofen; PC to mom on 15dec,mom stated t nl & pt back to school;
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications. In or around 2015, the patient was vaccinated with ZOSTAVAX (dose, route of administration, lot # and expiration date were not specified) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly thereafter, the patient developed a severe case of shingles, the first of several outbreaks. The first outbreak lasted three weeks, and after that event her immune system was suppressed, and she got pneumonia which hospitalized her. The patient required rehab to walk again. After her second outbreak, she was diagnosed with post herpetic neuralgia. As a result of vaccination the patient sustained personal injuries. Further, as a tragic consequence of vaccination the patient suffered serious injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. The outcome of the events of pneumonia and post herpetic neuralgia was not reported. The outcome of shingles was not recovered. The reporter considered the events to be related to ZOSTAVAX. Upon internal review, the events of shingles, immune system was suppressed and pneumonia were determined to be disabling. Upon internal review, the event of pneumonia was determined to be medically significant. Additional information has been requested.
pt stated that the morning after receiving the covid vax that she woke up  with a tender, red lump around the injection site.  She was weak and tired so went back to bed.  She had loss of appetite, congestion, heart palpitations and developed chills during the night.    She wakes up today 3/1/2021 weak and tired again today so went back today. She gets up about 2PM today with a red rash on her  neck, shoulders, back and all of the way around to her naval.   She says it looks like a shingles rash.  Pt is going to contact her PCP for medical advice.
Vaccine administered to Unapproved age. There wasn't any adverse effect at the time of compiling this report.
The patient got the ZOSTAVAX vaccine per protocol on Sunday June 25th, 2017. She felt her arm was warm and had the rash common with a local reaction but it was showing signs of cellulitis ( hardening under her skin) and she went to see CRNP who diagnosed her with cellulitis from the vaccine.
This case was reported by a consumer via call center representative and described the occurrence of systemic lupus erythematosus in a 69-year-old female patient who received Flu Seasonal TIV Dresden. In October 2016, the patient received Influenza. In October 2016, less than a month after receiving influenza vaccine  unspecified, the patient experienced systemic lupus erythematosus (serious criteria GSK medically significant) and seizure (serious criteria GSK medically significant). On an unknown date, the outcome of the systemic lupus erythematosus and seizure were unknown. It was unknown if the reporter considered the systemic lupus erythematosus and seizure to be related to influenza vaccine unspecified. Additional details were provided as follows: This case was reported by the patient's friend. the age at vaccination was not reported. the reporter contacted GlaxoSmithKline's (GSK) lupus line to discuss what was lupus and while in conversation, he reported that his friend had an influenza shot recently (unknown date) and experienced seizures and was diagnosed as having lupus. The reporter provided limited information.
Really bad muscle pain after 1st dose; Really bad joint pain after 1st dose; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 18-May-2021 and was forwarded to Moderna on 18-May-2021.    This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Really bad muscle pain after 1st dose) and ARTHRALGIA (Really bad joint pain after 1st dose) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025a21a and 028a21a) for COVID-19 vaccination.     Concurrent medical conditions included COPD and Chronic bronchitis.   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYALGIA (Really bad muscle pain after 1st dose) and ARTHRALGIA (Really bad joint pain after 1st dose). The patient was treated with IBUPROFEN (ADVIL 12HOUR) for Pain, at an unspecified dose and frequency. At the time of the report, MYALGIA (Really bad muscle pain after 1st dose) and ARTHRALGIA (Really bad joint pain after 1st dose) outcome was unknown.          concomitant product details not provided. Patient  received the 1st dose of the Moderna COVID-19 vaccine on 26Feb2021. She says that within a week she had really bad muscle and joint pain. patient  says the pain was still there by the time of the 2nd dose on 26Mar2021. and the pain was unrelenting and very severe and it keeps her up at night.patient last saw her doctor almost a month ago and the doctor suggested to call to report the pain. patient  has been tested for inflammation and there is no inflammation on the blood tests. She says the pain went from a 1 to 2/10 to 8/10 after the vaccine. She says she is on Advil constantly.   patient  also mentions that she has COPD and chronic bronchitis and that at about the same time the joint pain began, her lungs seemed to feel better. She says her lungs are more flexible after the vaccine.
Employee calling to report a reaction after receiving a COVID-19 vaccine.  Vaccine Name -  Pfizer Vaccine Date - ?  9/11/2021 Is this your first or second dose- 2nd Date of symptom onset - ? 9/11/2021 Symptoms - ? heavy feeling, pain all over, joint pain in big joints all over the body, parasthesia of hands and feet (so bad she drops objects), employee states she can still walk and do things but it is hard. employee also stated that she has psoriatic arthritis and takes biologics for it but it was a month before the first dose COVID-19 vaccine as recommended.  Last day of work and shift - ? NA Home remedies-Employee stated she has been taking 1 gram of Tylenol twice a day for pain Any improvement- Tylenol helps the pain only  Recommendation- Advised employee to follow treatment plan of phycisian. Employee voiced understanding Employee of information ? Yes  Employee voiced any concerns ? No  Employee?s questions answered to employee?s satisfaction -Yes